Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective
Prostate Cancer & Prostatic Diseases, 07/11/2012
Stewart SB et al. – Initiating chemoprevention at ages when prostate cancer incidence is higher improves its cost–effectiveness profile. Only when assuming a constant risk reduction for all tumor grades, did finasteride fall below $100,000 per quality–adjusted life–year, but this finding was not upheld when accounting for side effects associated with the drug.